WebBackground: The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC) is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) were shown in the CHAARTED trial in patients with metastatic highvolume disease (HVD). Objective: To assess the impact of metastatic burden and to update … WebDec 1, 2024 · Metastatic castration naïve prostate cancer. 1. Introduction. With the widespread use of prostate-specific antigen (PSA) screening, more and more patients are being found with early prostate cancer; however, there are still many cases of de novo metastatic prostate cancer at the time of diagnosis.
Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for ...
WebObjectives: No uniformity exists in the definition of metastatic burden in metastatic hormone-naive prostate cancer (mHNPC) across clinical trials making their comparison challenging. We explored definition agreement and prognostic significance of bulky mHNPC according to the CHAARTED and LATITUDE trial. Materials and methods: Since 2014, 95 patients … WebMay 18, 2024 · Celestia S. Higano, MD. Findings from the CHAARTED, LATITUDE, and STAMPEDE trials 1-3 showed various results for adding docetaxel (Taxotere) or abiraterone acetate (Zytiga) to androgen deprivation therapy (ADT) in prostate cancer, and this kicked off a challenging issue for clinicians: Is it better to add docetaxel, abiraterone … philips ihg rate
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive
WebJun 3, 2024 · Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT ... WebBackground: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined WebSep 2, 2024 · Management of metastatic prostate cancer has undergone a revolution over the past decade with the introduction of several novel agents and repurposing of others. ... In an updated analysis of the CHAARTED trial, the median OS, the primary end point, was significantly improved in the 513 patients with high-volume disease (hazard … philip silano port chester